ExodusPoint Capital Management’s C4 Therapeutics CCCC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-580,195
Closed -$2.71M – 1727
2026
Q2
$2.71M Buy
580,195
+532,688
+1,121% +$1.82M 0.02% 705
2026
Q1
$125K Sell
47,507
-14,658
-24% -$34.5K ﹤0.01% 1425
2025
Q4
$119K Buy
+62,165
New +$147K ﹤0.01% 1427
2025
Q1
– Sell
-59,654
Closed -$215K – 1511
2024
Q4
$215K Buy
+59,654
New +$297K ﹤0.01% 1351
2023
Q2
– Sell
-10,551
Closed -$33K – 1881
2023
Q1
$33K Buy
+10,551
New +$62.1K ﹤0.01% 1677
2022
Q3
– Sell
-35,197
Closed -$265K – 1916
2022
Q2
$265K Buy
+35,197
New +$310K ﹤0.01% 1576

Other funds holding CCCC

ExodusPoint Capital Management's CCCC Position: Q3 2026 in Review

ExodusPoint Capital Management sold out of C4 Therapeutics (CCCC) in Q3 2026, closing a stake of 580,195 shares — an estimated $2.71M sold.

ExodusPoint Capital Management first reported a position in CCCC in Q2 2022 and held it in 6 quarters. The position peaked at $2.71M in Q2 2026. 152 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

  • ExodusPoint Capital Management reported no remaining C4 Therapeutics position as of Q3 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 580,195 C4 Therapeutics shares in Q3 2026, an estimated $2.71M.
  • ExodusPoint Capital Management first reported a position in C4 Therapeutics in Q2 2022 and held it in 6 quarters.
  • ExodusPoint Capital Management's C4 Therapeutics position peaked at $2.71M in Q2 2026.
  • 152 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on ExodusPoint Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.